Research

International study suggests improved treatment alternative for lymphoid leukemia

Discovering what they call the "Achilles' heel" for lymphoid leukemia, an international research team has tested a possible alternative treatment that eradicated the disease in mouse models. Reporting their results in the journal Cancer Cell, the scientists said the targeted molecular therapy described in their study could have direct implications for current treatment of Acute Lymphoid Leukemia (ALL) in people.

Led by researchers at Cincinnati Children's Hospital Medical Center and the Institut de recherches cliniques de Montreal (ICRM), the study found that leukemic cells depend on a protein called Gfi1 for survival. Removing the protein in mouse models of the disease weakened and killed the leukemia cells. Researchers said this should make the leukemia more susceptible to chemo and radiation therapies – the current frontline treatments for ALL.

"Chemo and radiation therapies are very non-specific and can be toxic to patients. Our findings suggest that combining the inhibition of Gfi1 with these treatments may allow the use of lower cytotoxic doses and directly benefit patients," said H. Leighton Grimes, PhD, co-senior investigator on the study and researcher in the divisions of Cellular and Molecular Immunology and Experimental Hematology at Cincinnati Children's.

Also collaborating was co-senior investigator, Tarik Möröy, PhD, president and scientific director of the ICRM in Montreal.

The researchers said the need for better treatment options is evident. Beside the potential toxicity of current therapeutic options, many ALL patients relapse after initial remission of their disease.

A cancer that affects blood cells and the immune system, ALL is the most common type of leukemia in children from infancy up to age 19, according to the Leukemia and Lymphoma Society of America. ALL occurs most often in the first decade of life but increases in frequency again in older individuals. According to the National Cancer Institute, the overall survival rate for all ages of people with ALL is 66.4 percent and 90.8 percent for children under the age of 5 years.

During the onset of a disease like ALL, cancer signals among cells activate a protein called p53, which is often referred to as the "guardian of the genome." A repressor of tumor growth, p53 normally initiates a DNA repair program that is supposed to induce programmed cell death to stop or slow down tumor progression.

In the case of ALL, the researchers said the disease relies on the Gfi1 protein to get around p53's tumor repressing capabilities by essentially overriding p53. Gfi1 has an important role in the normal development of lymphoid cells. But analyses of ALL mouse models and primary human tumors showed that Gfi1 is overexpressed in the disease state.

When the researchers removed Gfi1 in established mouse lymphoid tumors, the leukemia regressed through p53-induced cell death. Next, to see if removal of Gfi1 would be effective in modeled human ALL, the research team inserted T-cell leukemia cells from human patients into mice. Inhibiting Gfi1 in this instance stopped the progression of human leukemia in the animals without any harmful effects.

The scientists are continuing their research to see if results of the current study will be translatable to human patients.

Other collaborators on the study included co-first authors, James Phelan, PhD, a former graduate student in Grimes' laboratory (now a postdoctoral fellow at the National Cancer Institute of the National Institutes of Health), and Cyrus Khandanpour, MD, a former post-doctoral fellow in Dr. Möröy's laboratory (presently a physician scientist at University Hospital of the University of Duisburg-Essen in Germany).

Funding for the research came in part from the National Institutes of Health (grant numbers CA105152, CA159845, P30 DK090971), the Canadian Institutes of Health Research (MOP-84238, MOP-111011) the the Canada Research Chair program, Leukemia and Lymphoma Society of America, CancerFree Kids, Alex's Lemonade Stand, the German Cancer Fund, the Cole Foundation, a University of Cincinnati Cancer Therapeutics T32 training grant (T32-CA117846) and a Pelotonia Fellowship.

Most Popular Now

New particle can track chemo

Tracking the path of chemotherapy drugs in real time and at a cellular level could revolutionize cancer care and help doctors sort out why two patients might respond diff...

Read more

The effects of the Trans-Pacific Pa…

The Trans-Pacific Partnership (TPP) is a multi-national trade agreement now being considered by 12 countries. In an insightful commentary in Research in Social and Admini...

Read more

Global pharmaceutical industry call…

More than 80 leading international pharmaceutical, generics, diagnostics and biotechnology companies, as well as key industry bodies, have come together to call on govern...

Read more

Human medicines: highlights of 2015

The European Medicines Agency (EMA) has released an overview of its 2015 key recommendations in relation to the marketing authorisations of new medicines and the safety m...

Read more

Merck announces new biopharma heads…

Merck, a leading science and technology company, today announced two appointments in two regions important for its biopharma business. Gary Zieziula will lead Merck's bio...

Read more

Leading medical journals propose ma…

The International Committee of Medical Journal Editors (ICMJE) proposes new rules that will require authors to share clinical trial data as a prerequisite for their manus...

Read more

Boehringer Ingelheim and Arena Phar…

Boehringer Ingelheim and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) have signed an exclusive agreement to conduct joint research to identify drug candidates targeting an ...

Read more

Merck launches Vivera in Latin Amer…

Merck, a leading science and technology company, today announced the launch of its new consumer brand Vivera® in Latin America. Vivera is being launched first in Chile in...

Read more

New drug could be safer, non-addict…

Researchers at Tulane University and Southeast Louisiana Veterans Health Care System have developed a painkiller that is as strong as morphine but isn't likely to be addi...

Read more

European Commission confirms CMDh r…

The European Commission (EC) has taken an EU-wide legally binding decision and confirmed the favorable benefit/risk profile of ambroxol and bromhexine containing medicine...

Read more

FDA approves first drug to show sur…

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue...

Read more

Ancient medicinal clay shows promis…

Naturally occurring clay from British Columbia, Canada - long used by the region's Heiltsuk First Nation for its healing potential - exhibits potent antibacterial activit...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]